Traffic exposure in a population with high prevalence type 2 diabetes - Do medications influence concentrations of C-reactive protein?

Environmental Pollution

Volumn 159, Issue 8-9, 2011, Pages 2051-2060

  Rioux, Christine L ^a   Tucker, Katherine L ^b   Brugge, Doug ^a   Gute, David M ^c   Mwamburi, Mkaya ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c Tufts University   (United States)

Author keywords

C reactive protein; Inflammation; Puerto; Residential traffic exposure; Rican; Traffic density; Traffic proximity; Type 2 diabetes

Indexed keywords

C-REACTIVE PROTEINS; INFLAMMATION; PUERTO; RESIDENTIAL TRAFFIC EXPOSURE; RICAN; TRAFFIC DENSITY; TYPE-2 DIABETES;

AIR QUALITY; INSULIN; PATHOLOGY;

PROTEINS;

C REACTIVE PROTEIN; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

AIR QUALITY; ATMOSPHERIC POLLUTION; DIABETES; DISEASE PREVALENCE; HEALTH IMPACT; POLLUTION EXPOSURE; PROTEIN; PUBLIC HEALTH; TRAFFIC EMISSION;

ADULT; AIR POLLUTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; EXHAUST GAS; FEMALE; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; TRAFFIC;

AGED; AIR POLLUTANTS; AIR POLLUTION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; VEHICLE EMISSIONS;

EID: 79958833151     PISSN: 02697491     EISSN: 18736424     Source Type: Journal    
DOI: 10.1016/j.envpol.2010.12.025     Document Type: Article

References (66)

1. American Diabetes Association, 2004. Diabetes Care 27 (Suppl. 1), S91-S93.
2. American Diabetes Association, 2006. Diagnosis and classification of diabetes mellitus. Diabetes Care 29 (Suppl. 1), S43-S48.
3. Babisch, W., 2006. Transportation noise and cardiovascular risk: updated review and synthesis of epidemiological studies indicate that the evidence has increased. Noise Health 8 (30), 1-29. (Pubitemid 46957239)
4. Bailey, C.J., 2005. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes. Metab. 7 (6), 675-691.
5. Barzilay, J.I., Abraham, L., Heckbert, S.R., Cushman, M., Kuller, L.H., Resnick, H.E., et al., 2001. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study. Diabetes 50 (10), 2384-2389. (Pubitemid 33641926)
6. Bateson, T.F., Schwartz, J., 2004. Who is sensitive to the effects of particulate air pollution on mortality? A case-crossover analysis of effect modifiers. Epidemiology 15 (2), 143-149. (Pubitemid 40416967)
7. Beckman, J.A., Creager, M.A., Libby, P., 2002. Diabetes and atherosclerosis epidemiology, pathophysiology, and management. J. Am. Med. Assoc. 287 (19), 2570-2581.
8. Bermudez, O.I., Tucker, K.L., 2001. Total and central obesity among elderly Hispanics and the association with type 2 diabetes. Obes. Res. 9 (8), 443-451.
9. Brugge, D., Durant, J.L., Rioux, C., 2007. Near-highway pollutants in motor vehicle exhaust: a review of epidemiologic evidence of cardiac and pulmonary health risks. Environ. Health Global Access Sci. Source 6.
10. Caballero, A.E., Delgado, A., Aguilar-Salinas, C.A., Herrera, A.N., Castillo, J.L., Cabrera, T., et al., 2004. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 89 (8), 3943-3948.
11. Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., Evans, R.M., 2001. PPAR-g dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7 (1), 48-52.
12. Chu, N.V., Kong, A.P.S., Kim, D.D., Armstrong, D., Baxi, S., Deutsch, R., et al., 2002. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25 (3), 542-549. (Pubitemid 41103350)
13. Creager, M.A., Lüscher, T.F., Cosentino, F., Beckman, J.A., 2003. Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108 (12), 1527-1532.
14. Dandona, P., 2008. Effects of antidiabetic and antihyperlipidemic agents on Creactive protein. Mayo Clin. Proc. 83 (3), 333-342.
15. Dandona, P., Aljada, A., Bandyopadhyay, A., 2004. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25 (1), 4-7. (Pubitemid 38032801)
16. De Jager, J., Kooy, A., Lehert, P., Bets, D., Wulffelé, M.G., Teerlink, T., et al., 2005. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med. (GBR) 257 (1), 100-109.
17. Delfino, R.J., Staimer, N., Tjoa, T., Polidori, A., Arhami, M., Gillen, D.L., et al., 2008. Circulating biomarkers of inflammation, antioxidant activity, and platelet activation are associated with primary combustion aerosols in subjects with coronary artery disease. Environ. Health Perspect. 116 (7), 898-906.
18. Dubowsky, S.D., Suh, H., Schwartz, J., Coull, B.A., Gold, D.R., 2006. Diabetes, obesity, and hypertension may enhance associations between air pollution and markers of systemic inflammation. Environ. Health Perspect. 114 (7), 992-998.
19. Duncan, B.B., Schmidt, M.I., Pankow, J.S., Ballantyne, C.M., Couper, D., Vigo, A., et al., 2003. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52 (7), 1799-1805. (Pubitemid 36792473)
20. Durant, J.L., Ash, C.A., Wood, E.C., Herndon, S.C., Jayne, J.T., Knighton, W.B., Canagaratna, M.R., Trull, J.B., Brugge, D., Zamore, W., Kolb, C., 2010. Short-term variation in near-highway air pollutant gradients on a winter morning. Atmos. Chem. Phys. 10, 8341-8352.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2002. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106, 3143-3421.
22. Festa, A., D'Agostino Jr., R., Howard, G., Mykkänen, L., Tracy, R.P., Haffner, S.M., 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 102 (1), 42-47. (Pubitemid 30430551)
23. Fleming, D.J., Jacques, P.F., Dallal, G.E., Tucker, K.L., Wilson, P.W.F., Wood, R.J., 1998. Dietary determinants of iron stores in a free-living elderly population: the framingham heart study. Am. J. Clin. Nutr. 67 (4), 722-733.
24. Ghanim, H., Dhindsa, S., Aljada, A., Chaudhuri, A., Viswanathan, P., Dandona, P., 2006. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J. Clin. Endocrinol. Metab. 91 (9), 3553-3558.
25. Gold, D.R., 2008. Vulnerability to cardiovascular effects of air pollution in people with diabetes. Curr. Diab. Rep. 8 (5), 333-335.
26. Haider, A.W., Larson, M.G., Franklin, S.S., Levy, D., 2003. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the framingham heart study. Ann. Intern. Med. 138 (1), 10-16.
27. Hsueh, W.A., Lyon, C.J., Quiñones, M.J., 2004. Insulin resistance and the endothelium. Am. J. Med. 117 (2), 109-117.
28. Inoue, H., Tanabe, T., Umesono, K., 2000. Feedback control of cyclooxygenase-2 expression through PPARg. J. Biol. Chem. 275 (36), 28028-28032.
29. Inzucchi, S.E., 2002. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J. Am. Med. Assoc. 287 (3), 360-372.
30. Jiang, C., Ting, A.T., Seed, B., 1998. PPAR-g agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (6662), 82-86. (Pubitemid 28079219)
31. Libby, P., 2002. Atherosclerosis: the new view. Sci. Am. 286 (5), 46.
32. MedlinePlus [Internet]. Bethesda (MD): national Library of Medicine (US); [updated 2010 April 30].
33. Blood Differential; [updated 2009 Feb 23; reviewed 2010 April 30; cited 2010 April 30]; [about 2 p.]. Available from: http://www.nlm.nih.gov/ medlineplus/ency/article/003657.htm.
34. Mohanty, P., Aljada, A., Ghanim, H., Hofmeyer, D., Tripathy, D., Syed, T., et al., 2004. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89 (6), 2728-2835.
35. National Institutes of Health, 2000. The Practical Guide to the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. U.S. National Institutes of Health, Bethesda, MD.
36. O'Neill, M.S., Veves, A., Zanobetti, A., Sarnat, J.A., Gold, D.R., Economides, P.A., et al., 2005. Diabetes enhances vulnerability to particulate air pollution-associated impairment in vascular reactivity and endothelial function. Circulation 111 (22), 2913-2920. (Pubitemid 40814183)
37. O'Neill, M.S., Veves, A., Sarnat, J.A., Zanobetti, A., Gold, D.R., Economides, P.A., et al., 2007. Air pollution and inflammation in type 2 diabetes: a mecnanism for susceptibility. Occup. Environ. Med. 64 (6), 373-379.
38. Ostro, B., Broadwin, R., Green, S., Feng, W.-, Lipsett, M., 2006. Fine particulate air pollution and mortality in nine california counties: results from CALFINE. Environ. Health Perspect. 114 (1), 29-33.
39. Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon III, R.O., Criqui, M., et al., 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation 107 (3), 499-511.
40. Pfeiffer, C.M., Caudill, S.P., Gunter, E.W., Osterloh, J., Sampson, E.J., 2005. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the national health and nutrition examination survey 1999-2000. Am. J. Clin. Nutr. 82 (2), 442-450.
41. Pickup, J.C., Mattock, M.B., Chusney, G.D., Burt, D., 1997. NIDDM as a disease of the innate immune system: association of acute- phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40 (11), 1286-1292. (Pubitemid 27469668)
42. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E., Ridker, P.M., 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J. Am. Med. Assoc. 286 (3), 327-334.
43. Quay, J.L., Reed, W., Samet, J., Devlin, R.B., 1998. Air pollution particles induce IL-6 gene expression in human airway epithelial cells via NF-kB activation. Am. J. Respir. Cell Mol. Biol. 19 (1), 98-106.
44. Ridker, P.M., Rifai, N., Pfeifer, M.A., Sacks, F., Braunwald, E., 1999. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100 (3), 230-235. (Pubitemid 29340127)
45. Riediker, M., Cascio, W.E., Griggs, T.R., Herbst, M.C., Bromberg, P.A., Neas, L., et al., 2004. Particulate matter exposure in cars is associated with cardiovascular effects in healthy young men. Am. J. Respir. Crit. Care. Med. 169 (8), 934-940.
46. Rioux, C.L., Tucker, K.L., Mwamburi, M., Gute, D.M., Brugge, D., 2010a. Residential traffic exposure, pulse pressure and C-reactive protein: consistency and contrast among exposure characterization methods. Environ. Health Perspect. doi:10.1289/ehp.0901182 Online February 2, 2010.
47. Rioux, C.L., Gute, D.M., Brugge, D., Peterson, S., Parmenter, B., 2010b. Characterizing urban traffic exposures using transportation planning tools: an illustrated methodology for health researchers. Urban Health, 1-22.
48. Rückerl, R., Ibald-Mulli, A., Koenig, W., Schneider, A., Woelke, G., Cyrys, J., et al., 2006. Air pollution and markers of inflammation and coagulation in patients with coronary heart disease. Am. J. Respir. Crit. Care. Med. 173 (4), 432-444.
49. Schins, R.P.F., Donaldson, K., 2000. Nuclear factor kappa-B activation by particles and fibers. Inhal. Toxicol. 12 (Suppl. 3), 317-326.
50. Schneider, A., Neas, L., Herbst, M.C., Case, M., Williams, R.W., Cascio, W., et al., 2008. Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals. Environ. Health Perspect. 116 (12), 1666-1674.
51. Shoelson, S.E., Lee, J., Goldfine, A.B., 2006. Inflammation and insulin resistance. J. Clin. Invest. 116 (7), 1793-1801.
52. Shoelson, S.E., Herrero, L., Naaz, A., 2007. Obesity, inflammation, and insulin resistance. Gastroenterology 132 (6), 2169-2180. (Pubitemid 46693756)
53. Shukla, A., Timblin, C., BeruBe, K., Gordon, T., McKinney, W., Driscoll, K., et al., 2000. Inhaled particulate matter causes expression of nuclear factor (NF)-κB-related genes and oxidant-dependent NF-κB activation in vitro. Am. J. Respir. Cell Mol. Biol. 23 (2), 182-187.
54. Stern, S.E., Williams, K., Ferrannini, E., DeFronzo, R.A., Bogardus, C., Stern, M.P., 2005. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54 (2), 333-339.
55. The Diabetes Prevention Program Research Group (DPPRG), 2005. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54 (5), 1566-1572.
56. Tucker, K.L., 2005. Stress and nutrition in relation to excess development of chronic disease in puerto rican adults living in the northeastern USA. J. Med. Invest. 52 (Suppl.), 252-258.
57. Tucker, K.L., Bermudez, O.I., Castaneda, C., 2000. Type 2 diabetes is prevalent and poorly controlled among hispanic elders of caribbean origin. Am. J. Public Health 90 (8), 1288-1293. (Pubitemid 30497384)
58. Tucker, K.L., Mattei, J., Noel, S.E., Collado, B.M., Mendez, J., Nelson, J., Griffith, J., Ordovas, J.M., Falcon, L.M., 2010. The Boston puertorican health study, a longitudinal cohort study on health disparities in puerto rican adults: challenges and opportunities. BMC Public Health 10, 107. doi:10.1186/1471-2458-10-107.
59. US Health and Human Services, January 24, 2007. The 2007 health and human service poverty guidelines. Fed. Regist. 72 (No. 15), 3147-3148.
60. Visser, M., Kritchevsky, S.B., Newman, A.B., Goodpaster, B.H., Tylavsky, F.A., Nevitt, M.C., et al., 2005. Lower serum albumin concentration and change in muscle mass: the health, aging and body composition study. Am. J. Clin.Nutr. 82 (3), 531-537.
61. Yudkin, J.S., Stehouwer, C.D.A., Emeis, J.J., Coppack, S.W., 1999. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19 (4), 972-978.
62. Yudkin, J.S., Kumari, M., Humphries, S.E., Mohamed-Ali, V., 2000. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 148 (2), 209-214.
63. Yue, W., Schneider, A., Stölzel, M., Rückerl, R., Cyrys, J., Pan, X., et al., 2007. Ambient source-specific particles are associated with prolonged repolarization and increased levels of inflammation in male coronary artery disease patients. Mutat. Res. Fundam. Mol. Mech. Mutagen. 621 (1-2), 50-60.
64. Zanobetti, A., Schwartz, J., 2002. Cardiovascular damage by airborne particles: are diabetics more susceptible? Epidemiology 13 (5), 588-592.
65. Zingarelli, B., Cook, J.A., 2005. Peroxisome proliferator-activated receptor-γ is a new therapeutic target in sepsis and inflammation. Shock 23 (5), 393-399. (Pubitemid 40571660)
66. 2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J. Immunol.171 (12), 6827-6837.